Abstract
Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. In this article, we outlined the decisions made regarding the practice of gastrointestinal oncology in our institution during the COVID pandemic.
Highlights
A case of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan City, China in December 2019
We examined the following questions: 1. What is the status of COVID-19 in Tokyo? 2
We outlined the recommendations for making decisions on chemotherapies for GI cancers during the COVID pandemic
Summary
A case of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan City, China in December 2019. As first-line chemotherapy, for patients with high tumor burden or tumor-related signs/symptoms or low risk of COVID-19 infection, combination of fluoropyrimidine and oxaliplatin (if HER2 is positive, plus trastuzumab) is recommended as a standard regimen [38]. SOX S-1 plus oxaliplatin; DS docetaxel plus S-1; Tmab trastuzumab; PTX paclitaxel; RAM ramucirumab; BSC best supportive care; FTD/TPI trifluridine/tipiracil; IRI Irinotecan a Low risk is defined as the presence of no risk factor b High risk is defined as the presence of one or more risk factors c HER2 positive case: + Tmab cycles, or stopping) should be considered, especially for patients with high-risk factors of COVID-19 infection.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
